Post-ganglionic autonomic neuropathy associated with anti-glutamic acid decarboxylase antibodies

E. Fileccia, R. Rinaldi, Rocco Liguori, Alex Incensi, R. D’Angelo, M. Giannoccaro, Vincenzo Angelo Donadio

Research output: Contribution to journalArticle

Abstract

Purpose: Antibodies to glutamic acid decarboxylase (GAD-Abs) have been associated with several conditions, rarely involving the autonomic nervous system. Here, we describe two patients complaining of autonomic symptoms in whom a post-ganglionic autonomic neuropathy has been demonstrated in association with significantly elevated serum and CSF GAD-Abs levels. Methods: Patients underwent nerve conduction studies, sympathetic skin response testing, evaluation of autonomic control of the cardiovascular system and skin biopsy. Also, serum screening to exclude predisposing causes of peripheral neuropathy was performed. Anti-GAD65 antibodies were evaluated in serum and CSF. Results: GAD-Abs titer was increased in both serum and CSF in both patients. Sympathetic skin response was absent and skin biopsy revealed a non-length-dependent small-fiber neuropathy with sympathetic cholinergic and adrenergic post-ganglionic damage in both patients. Nerve conduction studies and evaluation of autonomic control of the cardiovascular system were normal in both patients. Both patients were treated with steroids with good, but partial, (patient 2) recovery of the autonomic dysfunctions. Conclusions: Although the pathophysiological mechanisms involved are not fully defined, GAD-abs positivity in serum and CSF should be searched in patients with autonomic neuropathy when no other acquired causes are evident. This positivity may help to clarify autoimmune etiology and, subsequently, to consider immunomodulatory treatment.

Original languageEnglish
Pages (from-to)51-5
Number of pages5
JournalClinical Autonomic Research
Volume27
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Glutamate Decarboxylase
Antibodies
Serum
Skin
Neural Conduction
Cardiovascular System
Biopsy
Autonomic Nervous System
Peripheral Nervous System Diseases
Adrenergic Agents
Cholinergic Agents
Anti-Idiotypic Antibodies
Steroids

Keywords

  • Anti-GAD antibodies
  • Anti-glutamic acid decarboxylase antibodies
  • Autonomic neuropathy
  • Post-ganglionic autonomic neuropathy
  • Skin biopsy

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Clinical Neurology

Cite this

Post-ganglionic autonomic neuropathy associated with anti-glutamic acid decarboxylase antibodies. / Fileccia, E.; Rinaldi, R.; Liguori, Rocco; Incensi, Alex; D’Angelo, R.; Giannoccaro, M.; Donadio, Vincenzo Angelo.

In: Clinical Autonomic Research, Vol. 27, No. 1, 2017, p. 51-5.

Research output: Contribution to journalArticle

@article{69e74a21e7054b49b947237cca3a5863,
title = "Post-ganglionic autonomic neuropathy associated with anti-glutamic acid decarboxylase antibodies",
abstract = "Purpose: Antibodies to glutamic acid decarboxylase (GAD-Abs) have been associated with several conditions, rarely involving the autonomic nervous system. Here, we describe two patients complaining of autonomic symptoms in whom a post-ganglionic autonomic neuropathy has been demonstrated in association with significantly elevated serum and CSF GAD-Abs levels. Methods: Patients underwent nerve conduction studies, sympathetic skin response testing, evaluation of autonomic control of the cardiovascular system and skin biopsy. Also, serum screening to exclude predisposing causes of peripheral neuropathy was performed. Anti-GAD65 antibodies were evaluated in serum and CSF. Results: GAD-Abs titer was increased in both serum and CSF in both patients. Sympathetic skin response was absent and skin biopsy revealed a non-length-dependent small-fiber neuropathy with sympathetic cholinergic and adrenergic post-ganglionic damage in both patients. Nerve conduction studies and evaluation of autonomic control of the cardiovascular system were normal in both patients. Both patients were treated with steroids with good, but partial, (patient 2) recovery of the autonomic dysfunctions. Conclusions: Although the pathophysiological mechanisms involved are not fully defined, GAD-abs positivity in serum and CSF should be searched in patients with autonomic neuropathy when no other acquired causes are evident. This positivity may help to clarify autoimmune etiology and, subsequently, to consider immunomodulatory treatment.",
keywords = "Anti-GAD antibodies, Anti-glutamic acid decarboxylase antibodies, Autonomic neuropathy, Post-ganglionic autonomic neuropathy, Skin biopsy",
author = "E. Fileccia and R. Rinaldi and Rocco Liguori and Alex Incensi and R. D’Angelo and M. Giannoccaro and Donadio, {Vincenzo Angelo}",
note = "Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Universit{\`a} di Bologna (Liguori Rocco)",
year = "2017",
doi = "10.1007/s10286-016-0390-6",
language = "English",
volume = "27",
pages = "51--5",
journal = "Clinical Autonomic Research",
issn = "0959-9851",
publisher = "D. Steinkopff-Verlag",
number = "1",

}

TY - JOUR

T1 - Post-ganglionic autonomic neuropathy associated with anti-glutamic acid decarboxylase antibodies

AU - Fileccia, E.

AU - Rinaldi, R.

AU - Liguori, Rocco

AU - Incensi, Alex

AU - D’Angelo, R.

AU - Giannoccaro, M.

AU - Donadio, Vincenzo Angelo

N1 - Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Università di Bologna (Liguori Rocco)

PY - 2017

Y1 - 2017

N2 - Purpose: Antibodies to glutamic acid decarboxylase (GAD-Abs) have been associated with several conditions, rarely involving the autonomic nervous system. Here, we describe two patients complaining of autonomic symptoms in whom a post-ganglionic autonomic neuropathy has been demonstrated in association with significantly elevated serum and CSF GAD-Abs levels. Methods: Patients underwent nerve conduction studies, sympathetic skin response testing, evaluation of autonomic control of the cardiovascular system and skin biopsy. Also, serum screening to exclude predisposing causes of peripheral neuropathy was performed. Anti-GAD65 antibodies were evaluated in serum and CSF. Results: GAD-Abs titer was increased in both serum and CSF in both patients. Sympathetic skin response was absent and skin biopsy revealed a non-length-dependent small-fiber neuropathy with sympathetic cholinergic and adrenergic post-ganglionic damage in both patients. Nerve conduction studies and evaluation of autonomic control of the cardiovascular system were normal in both patients. Both patients were treated with steroids with good, but partial, (patient 2) recovery of the autonomic dysfunctions. Conclusions: Although the pathophysiological mechanisms involved are not fully defined, GAD-abs positivity in serum and CSF should be searched in patients with autonomic neuropathy when no other acquired causes are evident. This positivity may help to clarify autoimmune etiology and, subsequently, to consider immunomodulatory treatment.

AB - Purpose: Antibodies to glutamic acid decarboxylase (GAD-Abs) have been associated with several conditions, rarely involving the autonomic nervous system. Here, we describe two patients complaining of autonomic symptoms in whom a post-ganglionic autonomic neuropathy has been demonstrated in association with significantly elevated serum and CSF GAD-Abs levels. Methods: Patients underwent nerve conduction studies, sympathetic skin response testing, evaluation of autonomic control of the cardiovascular system and skin biopsy. Also, serum screening to exclude predisposing causes of peripheral neuropathy was performed. Anti-GAD65 antibodies were evaluated in serum and CSF. Results: GAD-Abs titer was increased in both serum and CSF in both patients. Sympathetic skin response was absent and skin biopsy revealed a non-length-dependent small-fiber neuropathy with sympathetic cholinergic and adrenergic post-ganglionic damage in both patients. Nerve conduction studies and evaluation of autonomic control of the cardiovascular system were normal in both patients. Both patients were treated with steroids with good, but partial, (patient 2) recovery of the autonomic dysfunctions. Conclusions: Although the pathophysiological mechanisms involved are not fully defined, GAD-abs positivity in serum and CSF should be searched in patients with autonomic neuropathy when no other acquired causes are evident. This positivity may help to clarify autoimmune etiology and, subsequently, to consider immunomodulatory treatment.

KW - Anti-GAD antibodies

KW - Anti-glutamic acid decarboxylase antibodies

KW - Autonomic neuropathy

KW - Post-ganglionic autonomic neuropathy

KW - Skin biopsy

UR - http://www.scopus.com/inward/record.url?scp=85000956491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000956491&partnerID=8YFLogxK

U2 - 10.1007/s10286-016-0390-6

DO - 10.1007/s10286-016-0390-6

M3 - Article

C2 - 27913968

AN - SCOPUS:85000956491

VL - 27

SP - 51

EP - 55

JO - Clinical Autonomic Research

JF - Clinical Autonomic Research

SN - 0959-9851

IS - 1

ER -